Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese

[1]  M. Kawashima,et al.  Finasteride in the treatment of Japanese men with male pattern hair loss. , 2004, European journal of dermatology : EJD.

[2]  S. Kaneko,et al.  Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. , 2004, British journal of clinical pharmacology.

[3]  A. Rodgers,et al.  Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. , 2003, European journal of dermatology : EJD.

[4]  Honghao Zhou,et al.  Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  K. Kaufman,et al.  Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. , 2002, Journal of the American Academy of Dermatology.

[6]  Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. , 2002, European journal of dermatology : EJD.

[7]  Honglu Zhang,et al.  A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[8]  A. Tosti,et al.  Finasteride increases anagen hair in men with androgenetic alopecia , 2000, The British journal of dermatology.

[9]  K. Kaufman.  Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss. , 1999, Archives of dermatology.

[10]  K. Kaufman,et al.  Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia. , 1999, Expert opinion on investigational drugs.

[11]  J. Hilbert,et al.  Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin , 1998, Journal of clinical pharmacology.

[12]  J. Shapiro,et al.  Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. , 1998, Journal of the American Academy of Dermatology.

[13]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[14]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[15]  J. Cavanaugh,et al.  Assessment of the Pharmacokinetic ‐Pharmacodynamic Interaction Between Terazosin and Finasteride , 1996, Journal of clinical pharmacology.

[16]  J F Steiner,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Finasteride , 1996, Clinical pharmacokinetics.

[17]  R. Miller,et al.  Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Kaoru Kobayashi,et al.  Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.

[19]  P. Roylance,et al.  Current treatment of BPH. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[21]  D. Waxman,et al.  Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. , 1994, Archives of biochemistry and biophysics.

[22]  Y. Nd.  Omeprazole: short- and long-term safety. , 1994 .

[23]  N. Yeomans.  Omeprazole: short- and long-term safety. , 1994, Adverse drug reactions and toxicological reviews.

[24]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[25]  K. Chiba,et al.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.

[26]  M. Quina,et al.  Omeprazole in the treatment of peptic ulcers resistant to H2‐receptor antagonist , 1990, Alimentary pharmacology & therapeutics.

[27]  W. Kalow,et al.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. , 1985, British journal of clinical pharmacology.

[28]  U. Haglund,et al.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.